Spain / 5 Key Industry Trends 2021
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
Research in neuroscience has a longstanding tradition in Spain mostly inspired by Nobel Prize winner Santiago Ramón y Cajal and his disciples, for whom the “Instituto Cajal” (IC) was initially conceived in 1934. Five years later the Spanish Government created the National Research Council under the name of Consejo Superior de Investigaciones Cientificas (CSIC) and the IC became one of the first centers of this new Institution. The IC is one of the two CSIC centers fully devoted to research in Neuroscience. The Institute moved to its present location in downtown Madrid in a building of 4,500 m2 in 1989. Currently the IC houses 25 independent research teams and around 200 staff, with operating costs close to 9 K€/year.
From its inception the Cajal Institute has contributed to the advance in Neuroscience and has hosted and formed many of the neuroscientists working now in the different Spanish research and academic centers. Along almost one century of life, the Institute has become a center of worldwide reputation, building on the important contributions of its founder to the present day. Current staff of the Institute has been selected under a tight competitive system according to the high standards of the CSIC. Presently, the institute is organized in two departments: Functional and Systems Neurobiology, and Cellular, Molecular and Developmental Neurobiology, which intend to agglutinate research in all major areas of neuroscience. The focus of the IC research can be comprised in five major lines:
– Mechanisms of neural specification
– The neuro-vascular unit
– Processing of neural signals (a new line of work in neuro-prosthetics and bioengineering is being planned to be incorporated in the near future to reinforce this section)
– Neuroprotection and regeneration
– Systemic modulators of brain function
Contact information:
Cajal Institute (CSIC)
Avenida Doctor Arce 37
28002 Madrid.
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona.…
Aiming to leverage European Union funds to reindustrialise its economy, the Spanish government has approved a public-private collaboration instrument to transform its health sector. The project looks to position Spain…
The deputy director of the Spanish Biosimilar Medicines Association (BioSim), Isabel del Río, comments on the current status of biosimilars in Spain – including the nearly EUR one billion in…
The latest from Spanish pharma, including Rovi’s better-than-expected 2021 results thanks to its Moderna partnership, the approval of Hipra’s COVID-19 IIb clinical trials, Sanifit Therapeutics’ acquisition by Vifor Pharma, and…
Walt Vernon is CEO of US-based healthcare facilities consulting firm, Mazzetti, and non-profit, Sextant. He is on the Board of the FGI and served on NFPA 99 ELS, NFPA 70…
The Lymphoma Coalition’s Natacha Bolaños outlines the fundamentals of the lymphoma patient experience today, the growing number of innovative new treatment options available, and the issues surrounding their integration as…
The Spanish pharma industry has entered the race to develop COVID-19 vaccines through an unexpected contender: an animal health company. HIPRA, headquartered in Catalonia, has received approval to begin human…
The latest from Spanish pharma, including the Patent and Trademark Office’s warning of the importance of IP protection for medical advancements, Grifols’ expansion in Africa through a manufacturing plant in…
The latest from Spanish pharma, including the acquisition of PTS by a private equity group for its nanoparticle drug delivery technologies; the agreement between Esteve and Kowa to license an…
The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being produced in the country, Grifols’ Egyptian entry, a new generation of leadership at…
A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a…
See our Cookie Privacy Policy Here